Quick Answer
ARROWHEAD PHARMACEUTICALS, INC. reported Net Income Loss of -$1.63 million for the year ending 2025.
- ARROWHEAD PHARMACEUTICALS, INC. showed an increase of +99.7% in Net Income Loss from 2024 to 2025.
- This data is from ARROWHEAD PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on November 25, 2025.
- XBRL data for this metric is available from 2005 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2010: -$1.44 million | Q1 2011: $2.91 million | Q2 2011: -$1.82 million | Q4 2011: -$2.49 million | Q1 2012: -$5.34 million | Q2 2012: -$7.99 million | Q4 2012: -$4.61 million | Q1 2013: -$6.76 million | Q2 2013: -$6.08 million | Q3 2013: -$13.69 million | Q4 2013: -$10.63 million | Q1 2014: -$13.94 million | Q2 2014: -$11.63 million | Q3 2014: -$22.43 million | Q4 2014: -$22.58 million | Q1 2015: -$28.68 million | Q2 2015: -$15.94 million | Q3 2015: -$24.75 million | Q4 2015: -$19.26 million | Q1 2016: -$20.82 million | Q2 2016: -$19.42 million | Q3 2016: -$22.22 million | Q4 2017: -$13.20 million | Q1 2018: -$14.88 million | Q2 2018: -$15.61 million | Q4 2018: $12.04 million | Q1 2019: $23.90 million | Q2 2019: $20.34 million | Q4 2019: -$2.67 million | Q1 2020: -$19.84 million | Q2 2020: -$13.61 million | Q4 2020: -$20.73 million | Q1 2021: -$26.82 million | Q2 2021: -$29.92 million | Q4 2021: -$62.87 million | Q1 2022: $44.37 million | Q2 2022: -$72.05 million | Q4 2022: -$41.33 million | Q1 2023: $48.68 million | Q2 2023: -$102.95 million | Q4 2023: -$132.86 million | Q1 2024: -$125.30 million | Q2 2024: -$170.79 million | Q4 2024: -$173.09 million | Q1 2025: $370.45 million | Q2 2025: -$175.24 million | Q4 2025: $30.81 million.
- Over the full 16 years of available data (2005 to 2025), ARROWHEAD PHARMACEUTICALS, INC.'s Net Income Loss has grown by 75.8%.
- Historical annual values: Fiscal year 2025: -$1.63 million | Fiscal year 2024: -$599.49 million | Fiscal year 2023: -$205.28 million | Fiscal year 2022: -$176.06 million | Fiscal year 2021: -$140.85 million | Fiscal year 2020: -$84.55 million | Fiscal year 2019: $67.98 million | Fiscal year 2018: -$54.45 million | Fiscal year 2017: -$34.38 million | Fiscal year 2016: -$81.72 million | Fiscal year 2015: -$91.94 million | Fiscal year 2014: -$58.63 million | Fiscal year 2013: -$31.14 million | Fiscal year 2012: -$21.13 million | Fiscal year 2011: -$3.13 million | Fiscal year 2005: -$6.73 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: